Difference between revisions of "Non-small cell lung cancer, BRAF-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 1: Line 1:
−
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
 
−
 
−
<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
 
 
{| class="wikitable" style="text-align:center; width:50%;"
 
{| class="wikitable" style="text-align:center; width:50%;"
 
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
 
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
Line 29: Line 26:
 
|}
 
|}
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
{| class="wikitable" style="width: 50%; text-align:center;"  
−
!style="width: 25%"|Study
+
!style="width: 33%"|Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Years of study
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928-untreated)]
 
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928-untreated)]
 +
|2014-2015
 
|style="background-color:#91cf61"|Phase II (RT)
 
|style="background-color:#91cf61"|Phase II (RT)
 
|-
 
|-
Line 60: Line 59:
 
|}
 
|}
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
{| class="wikitable" style="width: 50%; text-align:center;"  
−
!style="width: 25%"|Study
+
!style="width: 33%"|Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Years of study
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928-treated)]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928-treated)]
 +
|2013-2015
 
|style="background-color:#91cf61"|Phase II (RT)
 
|style="background-color:#91cf61"|Phase II (RT)
 
|-
 
|-
Line 77: Line 78:
  
 
===References===
 
===References===
−
# '''BRF113928:''' Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27283860 PubMed]
+
# '''BRF113928:''' Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. '''contains verified protocol''' [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30146-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27283860 PubMed]
  
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Lung cancers]]
 
[[Category:Lung cancers]]

Revision as of 20:24, 16 January 2020

Section editor
TravisOsterman.jpg
 Travis Osterman, DO, MS
Vanderbilt University
Nashville, TN
Social-twitter-icon.pngTravisOsterman
LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

3 regimens on this page
3 variants on this page


Advanced or metastatic disease, first-line

Dabrafenib & Trametinib

back to top

Regimen

FDA-recommended dose
Study Years of study Evidence
Planchard et al. 2017 (BRF113928-untreated) 2014-2015 Phase II (RT)

Biomarker Eligibility Criteria

  • Biomarker: BRAF V600E

Chemotherapy

Continued indefinitely

References

  1. BRF113928: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed

Advanced or metastatic disease, previously treated, BRAF inhibitor-naive

Dabrafenib & Trametinib

back to top

Regimen

FDA-recommended dose
Study Years of study Evidence
Planchard et al. 2016 (BRF113928-treated) 2013-2015 Phase II (RT)

All enrolled patients had progressed on 1 to 3 prior regimens.

Biomarker Eligibility Criteria

  • Biomarker: BRAF V600E

Chemotherapy

Continued indefinitely

References

  1. BRF113928: Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. contains verified protocol link to original article link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Non-small_cell_lung_cancer,_BRAF-mutated&oldid=42193"